Tempramed arranges $2.5-million private placement

Mr. Ron Nagar reports TEMPRAMED ANNOUNCES PRIVATE PLACEMENT OF UP TO C$2.5 MILLION Tempramed Technologies Ltd. has arranged a non-brokered private placement of up to 3,289,473 units of the company at a price of 76 cents per unit for aggregate gross proceeds of up to $2.5-million. Each unit will consist of one common share of the company and one share purchase warrant of the company. Each warrant will entitle the holder thereof to purchase one additional share at a price of $1 at any time on or before the date which is 18 months after the closing date of the offering. The proposed use of proceeds from the offering is to finance new inventory and product development, to scale the sales and marketing division globally, as well as for general working capital. In accordance with applicable securities laws, the shares, warrants and any additional shares issued upon exercise of the warrants will be subject to a four-month-and-one-day hold period in Canada from the date of closing of the offering. The warrants issued to certain of the investors will be subject to a restriction preventing their exercise if such exercise would result in the holder holding over 9.99 per cent of the issued and outstanding shares of the company. Accordingly, it is anticipated that there will be no new insiders as a result of the offering. Closing of the offering is anticipated to occur on or before Nov. 5, 2025, or such other date or dates as may be determined by the company, subject to the receipt of investor documentation, funds and compliance with the requirements of the Canadian Securities Exchange. In connection with the offering, the company may pay to certain qualified arm's-length parties finders' fees equal to 7 per cent of the gross proceeds raised and a number of finder shares equal to 7 per cent of the number of units placed by such finder. About Tempramed Technologies Ltd. Tempramed is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, FDA-registered (U.S. Food and Drug Administration), space-grade, hassle-free thermal insulation devices that work 24 hours a day, seven days a week for years without charging or external power. With a proven product line, including Vivi Cap and Vivi Epi, and a smart technology platform on the horizon, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed is advancing the future of medication protection and adherence. We seek Safe Harbor.